Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2 …
PA Goepfert, B Fu, AL Chabanon… - The Lancet Infectious …, 2021 - thelancet.com
Summary Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine
produced in a baculovirus expression system being developed against SARS-CoV-2. We …
produced in a baculovirus expression system being developed against SARS-CoV-2. We …
[HTML][HTML] Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo …
Y Zhang, G Zeng, H Pan, C Li, Y Hu, K Chu… - The Lancet infectious …, 2021 - thelancet.com
Background With the unprecedented morbidity and mortality associated with the COVID-19
pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac …
pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac …
[HTML][HTML] Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a …
S Sridhar, A Joaquin, MI Bonaparte… - The Lancet Infectious …, 2022 - thelancet.com
Background We evaluated our SARS-CoV-2 prefusion spike recombinant protein vaccine
(CoV2 preS dTM) with different adjuvants, unadjuvanted, and in a one-injection and two …
(CoV2 preS dTM) with different adjuvants, unadjuvanted, and in a one-injection and two …
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
R Ella, KM Vadrevu, H Jogdand, S Prasad… - The Lancet Infectious …, 2021 - thelancet.com
Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month …
R Ella, S Reddy, H Jogdand, V Sarangi… - The Lancet Infectious …, 2021 - thelancet.com
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel) …
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel) …
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of …
R Ella, S Reddy, H Jogdand, V Sarangi, B Ganneru… - medRxiv, 2020 - medrxiv.org
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 µg or 6 µg)
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) …
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) …
[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled …
W Guo, K Duan, Y Zhang, Z Yuan, YB Zhang… - …, 2021 - thelancet.com
Background We aimed to assess the safety and immunogenicity of an inactivated vaccine
against COVID-19 in Chinese adults aged≥ 18 years. Methods This is an ongoing …
against COVID-19 in Chinese adults aged≥ 18 years. Methods This is an ongoing …
[HTML][HTML] Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized …
G de Bruyn, J Wang, A Purvis, MS Ruiz… - …, 2023 - thelancet.com
Background In a parallel-group, international, phase 3 study (ClinicalTrials. gov
NCT04762680), we evaluated prototype (D614) and Beta (B. 1.351) variant recombinant …
NCT04762680), we evaluated prototype (D614) and Beta (B. 1.351) variant recombinant …
[HTML][HTML] Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled …
Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
[HTML][HTML] Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised …
ZR Yang, YW Jiang, FX Li, D Liu, TF Lin… - The Lancet …, 2023 - thelancet.com
Background The efficacy of SARS-CoV-2 vaccines in preventing severe COVID-19 illness
and death is uncertain due to the rarity of data in individual trials. How well the antibody …
and death is uncertain due to the rarity of data in individual trials. How well the antibody …